Compass Therapeutics, Inc. CMPX 深 滬
等待開盤 11-04 09:30:00 美东时间
0.753
-0.014
-1.89%
華盛通- 最 高0.7922
- 今 開0.7833
- 成交量 161.78万股
- 最 低 0.7443
- 昨 收 0.7675
- 總市值 1.36亿
- 52周最高 6.88
- 市盈率 靜 --
- 換手率 0.90%
- 52周最低 0.73
- 委 比 -25.13%
- 總股本 1.80亿
- 歷史最高 6.88
- 量 比 0.73
- 振 幅 6.24%
- 歷史最低 0.73
- 每 手 1
- 風險率 1.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Compass Therapeutics to Participate in Upcoming November Investor Events
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, announced its participation in two investor events: the Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026, and the Stifel 2026 Healthcare Conference on November 11, 2026. Both events will feature webcasts available on the company's Events page. Management will be available for one-on-one meetings, and interested investors should contact the...
11-02 14:00
Compass Therapeutics收涨4.01%，成交额225.08万美元
10月31日，Compass Therapeutics（CMPX）收涨4.01%，报0.79美元，成交额225.08万美元，市值1.42亿美元。 行情数据 •...
10-31 06:50
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
The COMPANION-002 study, published in the Journal of Clinical Oncology and presented at ESMO, demonstrated that tovecimig combined with paclitaxel significantly improved objective response rate (18.0% vs. 5.3%) and progression-free survival (4.7 vs. 2.6 months) in patients with previously treated advanced biliary tract cancer. The study also showed a 56% reduction in the risk of disease progression or death, durable responses (median DOR 4.9 mont...
10-24 08:15
Compass Therapeutics收跌5.05%，成交额162.53万美元
10月24日，Compass Therapeutics（CMPX）收跌5.05%，报0.76美元，成交额162.53万美元，市值1.37亿美元。 行情数据 •...
10-24 06:55
2026 ESMO|再鼎、石药、GSK等披露关键数据
（来源：药研网） 2026 ESMO官网已公布常规摘要全文，小编重点整理了再鼎、GSK、默沙东等公司的关键数据。 1 再鼎ZL-1310联合疗法 本文官...
10-20 17:40
Compass Therapeutics收跌4.09%，成交额177.92万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:52
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
Compass Therapeutics shares are trading lower after the company announced that the FDA recommended it conduct a trial demonstrating a survival benefit before proceeding with a Biologics License Application submission for tovecimig in patients with previously treated, advanced biliary tract cancer
Compass Therapeutics shares are trading lower after the company announced that the FDA recommended it conduct a trial demonstrating a survival benefit before proceeding with a Biologics License Application submission for tovecimig in patients with previously treated, advanced biliary tract cancer
09-22 20:45
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Piper Sandler Maintains Overweight on Compass Therapeutics, Raises Price Target to $6
Piper Sandler analyst Biren Amin maintains Compass Therapeutics (NASDAQ:CMPX) with a Overweight and raises the price target from $4 to $6.
08-08 00:58
